Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Polycythemia Vera 6Thrombocythemia, Essential 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Myeloproliferative Disorders 2Melanoma 2Solid Cancers 1Skin Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Neoplasms 1Neoplasm of Uncertain Malignant Potential 1Neoplasm Metastasis 1Leukemia, Myeloid, Acute 1Hepatitis C, Chronic 1Glioma 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Blast Crisis 1

Interventions

ledipasvir, sofosbuvir drug combination 2ledipasvir 2Ribavirin 2peginterferon alfa-2a 1daclatasvir 1Viusid 1Sofosbuvir 1Simeprevir 1Introns 1Dietary Supplements 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hepatitis C, Chronic × peginterferon alfa-2a × Clear all
NCT00630084 2015-09-04

Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma

Kaohsiung Medical University Chung-Ho Memorial Hospital

Phase 4 Completed
120 enrolled

Neoplasms, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡